29th Jun 2021 13:43
29 June 2021
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of GM
Cizzle Biotechnology, a UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, announces that at the General Meeting ("GM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.
The votes cast in respect of the resolutions were as follows:
Resolution | For | Against | Votes withheld | ||
Total votes | % | Total votes | % |
| |
1. That the Annual Report and Accounts for the year ended 31 December 2020 be received | 8,175,004 | 100.00% | 2 | 0.00% | 0 |
2. That PKF Littlejohn LLP be appointed as the Company's auditor | 8,175,004 | 100.00% | 2 | 0.00% | 0 |
3. That the directors be authorised to agree the remuneration of the auditor | 8,102,609 | 100.00% | 2 | 0.00% | 72,395 |
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
|
Allenby Capital Limited | +44(0) 20 33285656 |
John Depasquale |
|
Alex Brearley |
|
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis |
|
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe |
|
Florence Chandler |
|
About the Company
Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.
For more information please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Related Shares:
Cizzle Biotech